Találati lista | Tudóstér

001-es BibID:	BIBFORM054216
Első szerző:	Ajzner Éva (laboratóriumi szakorvos)
Cím:	Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding / É. Ajzner, I. Balogh, G. Haramura, Z. Boda, K. Kalmár, G. Pfliegler, B. Dahlbäck, L. Muszbek
Dátum:	2003
ISSN:	1538-7933
Megjegyzések:	Development of autoantibody against coagulation factor V (FV) is a rare clinical condition with hemorrhagic complications of varying severity. The aim of this study was to establish the pathomechanism of an acquired FV deficiency and characterize the FV inhibitor responsible for the clinical symptoms. A 78-year-old female was admitted to hospital with severe gastrointestinal bleeding. General clotting tests and determination of clotting factors were performed by standard methods. FV antigen and FV containing immune complexes were measured by ELISA. The FV molecule was investigated by Western blotting and by sequencing the f5 gene. The binding of patient's IgG to FV and activated FV (FVa) was demonstrated in an ELISA system and its effect on the procoagulant activity of FVa was tested in clotting tests and in a chromogenic prothrombinase assay. Localization of the epitope for the antibody was performed by blocking ELISA. FV activity was severely suppressed both in plasma and platelets. FV antigen levels were normal by ELISA using polyclonal anti-FV antibody or monoclonal antibody against the connecting region of FV, but depressed when HV1 monoclonal antibody against the C2 domain in the FV light-chain was used as capture antibody. The FV molecule was found intact. An IgG reacting with both FV and FVa was present in the patient's plasma and its binding to FV was inhibited by HV1 antibody. FV-containing immune complexes were detected in the patient's plasma and platelet lysate. The patient's IgG inhibited the procoagulant function of FVa. An anti-FV IgG was present in the patient's plasma and platelets. The autoantibody reacted with an epitope in the C2 domain of FV light chain and neutralized the procoagulant function of FVa.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Journal of thrombosis and haemostasis. - 1 : 5 (2003), p. 943-949. -
További szerzők:	Balogh István (1972-) (molekuláris biológus, genetikus) Haramura Gizella (1957-) (vezető analitikus) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Kalmár Kálmán Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Dahlbäck, Björn Muszbek László (1942-) (haematológus, kutató orvos)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM043325
035-os BibID:	PMID:11781258
Első szerző:	Ajzner Éva (laboratóriumi szakorvos)
Cím:	Severe coagulation factor V deficiency caused by 2 novel frameshift mutations : 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene / Éva Ajzner, István Balogh, Teréz Szabó, Anikó Marosi, Gizella Haramura, László Muszbek
Dátum:	2002
ISSN:	0006-4971
Megjegyzések:	A male infant with severe bleeding tendency had undetectable factor V activity. Sequence analysis of the proband's DNA revealed one base deletion in exon 13 (2952delT) and one base insertion in exon 16 (5493insG) in heterozygous form. Both mutations introduced a frameshift and a premature stop at codons 930 and 1776, respectively. The proband's father and mother were heterozygous for 2952delT and for 5493insG, respectively. Both mutations would result in the synthesis of truncated proteins lacking complete light chain or its C-terminal part. In the patient's plasma, no factor V light chain was detected by enzyme-linked immunosorbent assay. The N-terminal portion of factor V containing the heavy chain, and the connecting B domain was severely reduced but detectable (1.7%). A small amount of truncated factor V?specific protein with a molecular weight ratio of 236 kd could be immunoprecipitated from the plasma and detected by Western blotting. This protein, factor VDebrecen, corresponds to the translated product of exon 16 mutant allele.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Blood. - 99 : 2 (2002), p. 702-705. -
További szerzők:	Balogh István (1972-) (molekuláris biológus, genetikus) Szabó Terézia Marosi Anikó Haramura Gizella (1957-) (vezető analitikus) Muszbek László (1942-) (haematológus, kutató orvos)
Pályázati támogatás:	T030406 OTKA
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM034624
Első szerző:	Balogh István (molekuláris biológus, genetikus)
Cím:	Val34Leu polymorphism of plasma factor XIII : biochemistry and epidemiology in familial thrombophilia / István Balogh, Gabriella Szőke, Levente Kárpáti, Ulla Wartiovaara, Éva Katona, István Komáromi, Gizella Haramura, György Pfliegler, Hanna Mikkola, László Muszbek
Dátum:	2000
ISSN:	0006-4971
Megjegyzések:	Val34Leu polymorphism of the A subunit of coagulation factor XIII (FXIII-A) is located in the activation peptide (AP) just 3 amino acids away from the thrombin cleavage site. This mutation has been associated with a protective effect against occlusive arterial diseases and venous thrombosis; however, its biochemical consequences have not been explored. In the current study it was demonstrated that the intracellular stability and the plasma concentration of FXIII of different Val34Leu genotypes are identical, which suggests that there is no difference in the rate of synthesis and externalization of wild-type and mutant FXIII-A. In contrast, the release of AP by thrombin from the Leu34 allele proceeded significantly faster than from its wild-type Val34 counterpart. By molecular modeling larger interaction energy was calculated between the Leu34 variant and the respective domains of thrombin than between the Val34 variant and thrombin. In agreement with these findings, the activation of mutant plasma FXIII by thrombin was faster and required less thrombin than that of the wild-type variant. Full thrombin activation of purified plasma FXIII of different genotypes, however, resulted in identical specific transglutaminase activities. Similarly, the mean specific FXIII activity in the plasma was the same in the groups with wild-type, heterozygous, and homozygous variants. Faster activation of the Leu34 allele hardly could be associated with its presumed protective effect against venous thrombosis. No such protective effect was observed in a large group of patients with familial thrombophilia.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Blood. - 96 : 7 (2000), p. 2479-2486. -
További szerzők:	Szőke Gabriella Kárpáti Levente (1968-) (okleveles vegyész) Wartiovaara, Ulla Katona Éva (1961-) (klinikai biokémikus) Komáromi István (1957-) (vegyész, molekuláris biológus, biokémikus) Haramura Gizella (1957-) (vezető analitikus) Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Mikkola, Hanna Muszbek László (1942-) (haematológus, kutató orvos)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat Szerző által megadott URL
Borító:
Saját polcon:

001-es BibID:	BIBFORM058217
Első szerző:	Wartiovaara, Ulla
Cím:	Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A / U. Wartiovaara, H. Mikkola, G. Szőke, G. Haramura, L. Kárpáti, I. Balogh, R. Lassila, L. Muszbek, A. Palotie
Dátum:	2000
ISSN:	0340-6245
Megjegyzések:	Coagulation factor XIII (FXIII) is a protransglutaminase involved in the last step of the coagulation cascade by stabilising the fibrin clot. Recently, a common variation (FXIII Val34Leu) has been associated with a decreased risk of myocardial infarction and deep venous thrombosis. Val34Leu is critically located near the thrombin activation site of FXIII-A. In this study we investigated its effects on the activation of FXIII. Both recombinant and platelet-derived FXIII Val34Leu variants were shown to be more susceptible to thrombin cleavage than the wild type FXIII. The rate of enzymatic activation of FXIII Val34Leu was found increased, however, the specific activity of fully activated wild type FXIII and the Val34Leu mutant did not differ. During the course of thrombin-induced activation of FXIII fibrin gamma-chain dimerisation and alpha-chain polymerisation developed more rapidly with the Val34Leu mutant. The increased rate of fibrin stabilisation brought about by the Val34Leu FXIII seems to be paradoxically associated with a protective effect against pathological thrombosis.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Factor XIII Factor XII Val34Leu thrombin peptide
Megjelenés:	Thrombosis and Haemostasis. - 84 : 4 (2000), p. 595-600. -
További szerzők:	Mikkola, Hanna Szőke Gabriella Haramura Gizella (1957-) (vezető analitikus) Kárpáti L. Balogh István (1972-) (molekuláris biológus, genetikus) Lassila, Riitta Muszbek László (1942-) (haematológus, kutató orvos) Palotie, Aarno
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: